The present invention provides: novel compounds capable of producing monomethyl fumarate after the compounds are administered; pharmaceutical compositions comprising same as active ingredients; and pharmaceutical uses thereof for treating or alleviating various diseases including immune system abnormalities, neurodegeneration, and/or inflammatory diseases.

The compound is represented by general formula (i). In the compound, in a group K.sup.i1, at least two secondary carbon atoms in an alkyl group (a linear alkyl, halogenated alkyl, or cyanogenated alkyl group having 3 to 40 carbon atoms) are replaced with —C(═X.sup.i1)— and/or —CH(—CN)—, where X.sup.i1 is an oxygen atom, a sulfur atom, NH, or NR.sup.13; in addition, a group A.sup.i2, a group A.sup.i3, or the group K.sup.i1 includes, as a substituent, at least one P.sup.i1-Sp.sup.i1- group, where P.sup.i1 is a polymerizable group, and SP.sup.i1 is a spacer group or a single bond. The liquid crystal composition including the compound represented by general formula (i) can be adsorbed onto substrates between which a liquid crystal layer is held, and, consequently, without the use of an alignment film, liquid crystal molecules can be maintained in a state in which the liquid crystal molecules are aligned in a vertical direction. ##STR00001##

The compound is represented by general formula (i). In the compound, in a group K.sup.i1, at least two secondary carbon atoms in an alkyl group (a linear alkyl, halogenated alkyl, or cyanogenated alkyl group having 3 to 40 carbon atoms) are replaced with —C(═X.sup.i1)— and/or —CH(—CN)—, where X.sup.i1 is an oxygen atom, a sulfur atom, NH, or NR.sup.13; in addition, a group A.sup.i2, a group A.sup.i3, or the group K.sup.i1 includes, as a substituent, at least one P.sup.i1-Sp.sup.i1- group, where P.sup.i1 is a polymerizable group, and SP.sup.i1 is a spacer group or a single bond. The liquid crystal composition including the compound represented by general formula (i) can be adsorbed onto substrates between which a liquid crystal layer is held, and, consequently, without the use of an alignment film, liquid crystal molecules can be maintained in a state in which the liquid crystal molecules are aligned in a vertical direction. ##STR00001##

Provided are plants that express, or overexpress, a pPLAIIIδ protein. Constitutive or seed-specific expression of pPLAIIIδ protein in Arabidopsis increases seed oil content, the amount of C20 and C22 fatty acids, and the amount of C56, C58, and C60 triacylglycerols, effectively resulting in significantly higher oil yield per plant. Use of pPLAIIIδ is therefore an effective biotechnological tool to significantly increase plant yield, including oil, and the amount of high value long chain fatty acids in agricultural and horticultural crops, especially oilseed crops.

Provided are plants that express, or overexpress, a pPLAIIIδ protein. Constitutive or seed-specific expression of pPLAIIIδ protein in Arabidopsis increases seed oil content, the amount of C20 and C22 fatty acids, and the amount of C56, C58, and C60 triacylglycerols, effectively resulting in significantly higher oil yield per plant. Use of pPLAIIIδ is therefore an effective biotechnological tool to significantly increase plant yield, including oil, and the amount of high value long chain fatty acids in agricultural and horticultural crops, especially oilseed crops.

Described herein are methods of stabilizing the beta hydrogen of glycerol based esters by the insertion of alkoxy groups to significantly improve the thermal, oxidative, and hydrolytic stability of the ester and allow for controlling the molar density of esters bonds in the lubricants to maximize hydrolytic stability while maintaining biodegradability and further improving performance properties.

Described herein are methods of stabilizing the beta hydrogen of glycerol based esters by the insertion of alkoxy groups to significantly improve the thermal, oxidative, and hydrolytic stability of the ester and allow for controlling the molar density of esters bonds in the lubricants to maximize hydrolytic stability while maintaining biodegradability and further improving performance properties.

The use of bio oil from at least one renewable source in a hydrotreatment process, in which process hydrocarbons are formed from said glyceride oil in a catalytic reaction, and the iron content of said bio oil is less than 1 w-ppm calculated as elemental iron. A bio oil intermediate including bio oil from at least one renewable source and the iron content of said bio oil is less than 1 w-ppm calculated as elemental iron.

The use of bio oil from at least one renewable source in a hydrotreatment process, in which process hydrocarbons are formed from said glyceride oil in a catalytic reaction, and the iron content of said bio oil is less than 1 w-ppm calculated as elemental iron. A bio oil intermediate including bio oil from at least one renewable source and the iron content of said bio oil is less than 1 w-ppm calculated as elemental iron.

The use of bio oil from at least one renewable source in a hydrotreatment process, in which process hydrocarbons are formed from said glyceride oil in a catalytic reaction, and the iron content of said bio oil is less than 1 w-ppm calculated as elemental iron. A bio oil intermediate including bio oil from at least one renewable source and the iron content of said bio oil is less than 1 w-ppm calculated as elemental iron.